NSCLC has one of the most dynamic drug development pipelines in oncology, including multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust growth throughout the 2016-2026 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated label expansions of immune checkpoint inhibitors. Merck & ;s Keytruda became the first immune checkpoint inhibitor to receive approval for first-line NSCLC and is anticipated to generate significant sales in this setting. EGFR and ALK inhibitor drug classes will also contribute to market growth following the first-line label expansions of Tagrisso and Alecensa, respectively. Several new therapies will gain approvals within the forecast period, from four different drug classes, resulting in increased therapy options and a highly competitive market.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.